A Prospective, Randomized, Parallel group Study to Evaluate the Safety and Efficacy of FDC of Mupirocin calcium, Neomycin Sulfate & HT61 HCL in Patients with infected skin lesions by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) and or S. Pyogenes. - CRSC16001
Latest Information Update: 12 Nov 2019
At a glance
- Drugs HT-61/mupirocin/neomycin (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- Sponsors Cadila Pharmaceuticals
- 15 Dec 2017 New trial record